AI-Powered Embryo Selection - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The aI-powered embryo selection market is expected to grow from USD 177.75 million in 2025 to USD 195.59 million in 2026 and is forecasted to reach USD 346.82 million by 2031 at 12.14% CAGR over 2026-2031. This report is Segmented by Component (Software, Services), Deployment Mode (Cloud-Based, On-Premises), Technology (Deep Learning, Machine Learning, and More), Application (In Vitro Fertilization, and More), End-User (Fertility Clinics and IVF Centers, and More), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). Market Forecasts Provided in Terms of Value (USD).

Global AI-Powered Embryo Selection Market Trends and Insights

Rising Infertility and Delayed Parenthood

The AI-powered embryo selection market draws its core demand from the wide reach of infertility across adult populations, because the issue affects 17.5% of adults globally and shows little meaningful variation between higher-income and lower-income regions. That demand base is becoming more complex, because a 2025 study showed that global male infertility cases rose by 74.7% between 1990 and 2021, which pushes clinics toward more detailed assessment protocols instead of simpler, single-factor evaluation paths. The AI-powered embryo selection market also benefits from the growing weight of delayed parenthood, since later treatment entry often comes with tighter cycle economics and stronger pressure to avoid avoidable embryo selection errors. This creates a large and recurring clinical pool for the AI-powered embryo selection market, especially where patients are already paying heavily for each IVF attempt and want more disciplined ranking support. It also means clinics have stronger reasons to pay for tools that improve consistency when they serve older patients or patients coming into repeated transfer cycles.

Need To Reduce Subjectivity in Embryo Grading

The AI-powered embryo selection market is gaining traction because manual embryo grading still shows clear reproducibility limits in daily laboratory practice. Alife Health cited a 34.6% disagreement rate among specialists choosing the top embryo from a cohort, and the disagreement rose to 44% when 3 or more embryos were available for review. This matters commercially because clinics are no longer viewing embryo ranking as a purely individual judgment task, especially when different staff members may reach different conclusions on the same image set. The American Society for Reproductive Medicine stated in 2024 that AI systems can support more objective and more consistent evaluation inside the IVF laboratory, which gives the AI-powered embryo selection market a stronger clinical legitimacy base. As a result, the AI-powered embryo selection market is increasingly tied not only to outcome expectations, but also to auditability, repeatability, and clearer process control across multi-site fertility networks.

High Validation Burden for Clinical Deployment

The AI-powered embryo selection market faces a meaningful slowdown due to the cost and duration of clinical validation. In Europe, the EU AI Act classifies embryo selection software as high-risk AI, which means vendors must support explainability, risk controls, and post-market oversight alongside medical device obligations. These requirements extend development timelines and redirect spending toward documentation, validation, and monitoring instead of faster product iteration. This favors companies with established trial networks, existing compliance teams, and enough funding to manage multi-country submissions without pausing commercial execution. As a result, the AI-powered embryo selection market gives smaller vendors less room to compete quickly, even when their technical models perform well in early studies.

Other drivers and restraints analyzed in the detailed report include:

• Growing Adoption of Time-Lapse Imaging Workflows
• Expansion of Data-Rich Digital Fertility Ecosystems
• Uneven Reimbursement and Capital Budget Priorities in Fertility Care

Segment Analysis

Software held 52.83% of revenue in 2025 and is also expected to be the fastest-growing segment with 12.62% CAGR, that lead showed where commercial value is forming inside the AI-powered embryo selection market. Clinics have increasingly favored per-cycle or subscription pricing because it lowers the initial hurdle compared with buying new imaging hardware for every site. In this structure, adoption is tied more closely to laboratory throughput and clinical workflow use than to one-time procurement events.

The services layer remains important because integration, training, validation support, and workflow setup still affect whether a tool is used consistently after purchase. Over time, the winning component strategies in the AI-powered embryo selection market will likely remain those that combine recurring software revenue with enough service depth to keep clinics active after deployment.

Cloud-based deployment held 53.27% share in 2025 and is projected to expand at 13.18% CAGR through 2031, making it the leading deployment path in the AI-powered embryo selection market. That lead reflects the practical demands of time-lapse image storage, remote access, model updates, and cross-site workflow management. High-throughput IVF centers generate large image archives, and cloud architecture lets those sites avoid repeated local hardware expansion while keeping access available across laboratory teams. It also fits vendor economics, because cloud deployment supports centralized updates and more consistent model version control across many clinic locations.

On-premises deployment still remains relevant in settings where patient data rules, local governance preferences, or internal IT policies make external hosting harder to approve. Large networks are more likely to use cloud for coordination, analytics, and updates, while some clinics will preserve local deployment for control and governance reasons. The long-term result is a mixed deployment structure where the AI-powered embryo selection market supports both centralized scale and local compliance needs instead of forcing one uniform model.

Complete Report Scope:

• By Component
  • Software
  • Services
• By Deployment Mode
  • Cloud-Based
  • On-Premises
• By Technology
  • Deep Learning
  • Machine Learning
  • Computer Vision and Image Analytics
  • Predictive Analytics and Data Integration
  • Other Technologies
• By Application
  • In Vitro Fertilization
  • Embryo Viability Assessment
  • Embryo Monitoring and Morphokinetic Analysis
  • Cryopreservation and Embryo Storage
  • Research and Clinical Trials
• By End-User
  • Fertility Clinics and IVF Centers
  • Hospitals and Specialty Reproductive Centers
  • Research Institutes and Universities
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 45.74% of the AI-powered embryo selection market share in 2025, and that leadership reflected the region’s concentration of regulated products, advanced IVF networks, and venture-backed fertility technology activity. The AI-powered embryo selection market is more mature in North America because U.S. procurement committees place clear value on FDA status when they assess whether a tool is ready for routine clinical use. Private-pay fertility economics also support adoption, since out-of-pocket IVF cycles in the United States can range from USD 12,000 to USD 25,000 and leave room for premium add-on software within a patient-funded treatment model. This makes the AI-powered embryo selection market more commercially responsive in North America than in systems where reimbursement decides most technology spending.

Asia-Pacific is projected to be the fastest-growing regional slice of the AI-powered embryo selection market, with 15.31% CAGR projected through 2031. The region’s growth path is tied to a mix of high infertility burden, improving access to ART, and large addressable patient pools that can support software licensing over time. The AI-powered embryo selection market is especially well-positioned in Asia-Pacific, where treatment access is expanding, and clinics are seeking better cycle economics without adding invasive steps to every case. India stands out because a large number of infertile couple base to a growing IVF ecosystem, even though the rewritten analysis retains only the population-side evidence supported by UNFPA.

Europe remains structurally important to the AI-powered embryo selection market because it combines high IVF activity with demanding compliance standards that influence product design well beyond the region itself. The EU AI Act has made explainability, bias controls, and post-market monitoring more central for high-risk reproductive AI, which raises the bar for commercial entry while also pushing vendors toward more defensible model behavior. Germany’s stricter reproductive framework limits adoption more than in markets such as France, Belgium, or Spain, where broader use of AI-assisted selection fits more easily into clinical practice patterns. Middle East and Africa, along with South America, remain earlier-stage opportunities in the AI-powered embryo selection market, where private-pay centers will likely move ahead of publicly constrained systems as capital budgeting and reimbursement continue to shape adoption speed.

List of Companies Covered in this Report:

• AIVF Ltd.
• Boston IVF
• Cook Group
• The Cooper Companies
• DeepLife AI
• Esco Lifesciences
• Fairtility Ltd.
• Fujifilm Irvine Scientific, Inc.
• Genea Biomedx
• Hamilton Thorne Ltd.
• iGenomix
• IVI-RMA Global
• Merck
• Monash IVF Group
• Nikon
• Overture Life, Inc.
• Presagen
• TMRW Life Sciences
• Virtus Health
• Vitrolife
• Carl Zeiss

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support